may as well as AI as it seems to be the research tool of choice:
"does cf33 work"
response:
"Yes, the oncolytic virus CF33 shows promise in treating certain cancers, particularly those in the gastrointestinal tract like bile duct cancer. Early results from studies indicate a strong response, with some patients achieving complete or stable disease, according to Bioshares. One patient with bile duct cancer even achieved a complete response after three courses of chemotherapy and a low PD-L1 level, suggesting it may be effective even when other therapies fail. Here's a more detailed look:
Positive Results in Gastrointestinal Tumors:
Strong Disease Control:In studies with CF33, a high percentage of patients with gastrointestinal cancers have shown disease control (partial or full response, or stable disease), according to Bioshares.
Complete Response:
One patient with bile duct cancer achieved a complete response after receiving CF33 monotherapy, even after previous chemotherapy.
Stable Disease:
Another patient with bile duct cancer demonstrated stable disease for over five months after receiving CF33-hNIS."
"does Azer-Cell work"
response:
"Yes, there is evidence that azer-cel, an investigational allogeneic CAR-T therapy, is effective in treating certain cancers, particularly diffuse large B-cell lymphoma. Clinical trials have shown promising results, including complete responses, with the therapy being generally well-tolerated.
Here's a more detailed look:
What is Azer-cel?
Azer-cel is an allogeneic CAR-T therapy, meaning it uses T cells from a donor, not the patient themselves. These T cells are modified with a chimeric antigen receptor (CAR) to target and eliminate specific cancer cells.
How is Azer-cel used?
Azer-cel is being investigated in Phase 1b clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In some trials, it is combined with lymphodepletion (LD) and IL-2.
What are the results?
Studies have shown that azer-cel can achieve complete responses (CRs) in some patients with DLBCL. In a Phase 1b trial, two patients achieved complete responses that lasted over 90 and 120 days, respectively, and were maintained. The therapy is generally well-tolerated, with manageable side effects."
"does OnCARlytics work"
response:
"OnCARlytics, a combination of a modified oncolytic virus (CF33-CD19) and CD19-targeting therapies, has shown promise in pre-clinical trials for treating solid tumors. By expressing CD19 on tumor cells, it enables CAR T cell therapy to target and destroy these tumors, which are often difficult to treat with CAR T therapy alone.
Here's a more detailed explanation:
How it works:
OnCARlytics leverages the CF33 oncolytic virus to deliver and express CD19 on the surface of solid tumor cells. This makes the tumor cells "visible" to CD19-targeting therapies, such as CAR T cells, which can then recognize and destroy them.
Pre-clinical evidence:
In pre-clinical studies, onCARlytics has demonstrated superior potency against solid tumors compared to either CF33 or CD19 targeting therapy alone. It has been shown to effectively target and eradicate tumors in various models, including triple-negative breast, pancreatic, prostate, ovarian, brain, and head and neck cancers. "
(20min delay)